[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Daniel Emmett Clark net worth and biography

Daniel Clark Biography and Net Worth

General Counsel of GeneDx

Daniel E. Clark is a mission-driven advocate with over 15 years of legal experience. As General Counsel for Sema4, Dan oversees all legal and regulatory matters for the company. He also supports Sema4’s academic mission, having worked as a former Lecturer and Research Assistant at the University of Michigan.

Prior to joining Sema4, Dan worked with Eric Schadt, now Sema4’s CEO, and the Icahn Institute in a senior legal role to drive next generation research and industry partnerships. He also practiced in New York City with two leading law firms, clerked for a district judge in the Eastern District of New York, and helped found a boutique startup law firm.

Dan graduated with honors from the University of Michigan School of Law and Pomona College, and has travelled internationally as a Thomas J. Watson Fellow.

What is Daniel Emmett Clark's net worth?: The estimated net worth of Daniel Emmett Clark is at least $656,334.80 as of July 26th, 2022. Mr. Clark owns 9,460 shares of GeneDx stock worth more than $656,335 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Clark may own. Learn More about Daniel Emmett Clark's net worth.
How do I contact Daniel Emmett Clark?: The corporate mailing address for Mr. Clark and other GeneDx executives is 333 Ludlow Street North Tower 8th Floor, Stamford CT, 06902. GeneDx can also be reached via phone at 800-298-6470 and via email at [email protected]. Learn More on Daniel Emmett Clark's contact information.
Has Daniel Emmett Clark been buying or selling shares of GeneDx?: Daniel Emmett Clark has not been actively trading shares of GeneDx within the last three months. Most recently, Daniel Emmett Clark sold 38 shares of the business's stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $48.51, for a transaction totalling $1,843.38. Following the completion of the sale, the general counsel now directly owns 9,460 shares of the company's stock, valued at $458,904.60. Learn More on Daniel Emmett Clark's trading history.
Who are GeneDx's active insiders?: GeneDx's insider roster includes Shawn Assad (CAO), Daniel Clark (General Counsel), James Coffin (COO), Anthony Prentice (Insider), Isaac Ro (CFO), and Eric Schadt (CEO). Learn More on GeneDx's active insiders.
Are insiders buying or selling shares of GeneDx?: In the last year, GeneDx insiders bought shares 5 times. They purchased a total of 215,804 shares worth more than $4,121,270.44. In the last year, insiders at the sold shares 42 times. They sold a total of 1,856,727 shares worth more than $103,449,641.94. The most recent insider tranaction occured on November, 18th when Major Shareholder School Of Medicine At Mo Icahn sold 126,782 shares worth more than $8,973,629.96. Insiders at GeneDx own 27.3% of the company. Learn More about insider trades at GeneDx.
Information on this page was last updated on 11/18/2024.

Daniel Emmett Clark Insider Trading History at GeneDx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/26/2022	Sell	38	$48.51	$1,843.38	9,460
4/28/2022	Sell	36	$71.94	$2,589.84	9,380
1/28/2022	Sell	45	$93.72	$4,217.40
10/25/2021	Sell	38	$248.82	$9,455.16

Daniel Emmett Clark Buying and Selling Activity at GeneDx

GeneDx Company Overview

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $69.38

$68.04

$71.46

50 Day Range

MA: $58.11

$36.84

$84.02

2 Week Range

Now: $69.38

$1.29

$89.11

Volume

458,804 shs

Average Volume

451,000 shs

Market Capitalization

$1.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate